open access

Vol 26, No 1 (2019)
Letters to the Editors
Published online: 2019-03-14
Get Citation

Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update

Claudio Borghi, Krzysztof Narkiewicz, Giuseppe Mancia
DOI: 10.5603/CJ.2019.0015
·
Pubmed: 30882192
·
Cardiol J 2019;26(1):99-101.

open access

Vol 26, No 1 (2019)
Letters to the Editors
Published online: 2019-03-14

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update

Journal

Cardiology Journal

Issue

Vol 26, No 1 (2019)

Pages

99-101

Published online

2019-03-14

DOI

10.5603/CJ.2019.0015

Pubmed

30882192

Bibliographic record

Cardiol J 2019;26(1):99-101.

Authors

Claudio Borghi
Krzysztof Narkiewicz
Giuseppe Mancia

References (13)
  1. Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11): 649–662.
  2. Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018; 71(6): 851–865.
  3. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26(2): 186–191.
  4. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005; 25(1): 3–8.
  5. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42.
  6. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
  7. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016; 20(5): 983–992.
  8. White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200–1210.
  9. Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018; 57(suppl_1): i47–i50.
  10. Kojima S, Matsui K, Ogawa H, et al. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017; 69(1): 169–175.
  11. Kimura K, Hosoya T, Uchida S, et al. FEATHER Study Investigators. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6): 798–810.
  12. Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. Circulation. 2018; 138(11): 1116–1126.
  13. White WB. Gout, xanthine oxidase inhibition, and cardiovascular outcomes. Circulation. 2018; 138(11): 1127–1129.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl